Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon‐free therapy in hepatitis C virus genotype 1b

Background and Aim

Virologic failure of interferon‐free therapy has been associated with Y93H mutation in the non‐structure 5A region in hepatitis C virus (HCV) genotype 1b, and screening is recommended. A simple assay based on Q‐Invader technology was developed for Y93H mutant screening to reduce cost and effort. The present study sought to compare two methods of detection of Y93H mutation and to evaluate the effect of Y93H mutation on response to interferon‐free therapy.

Methods

Y93H mutation was examined in 258 patients with HCV genotype 1b using both direct sequencing analysis and the polymerase chain reaction (PCR)‐Invader assay. Daclatasvir and asunaprevir or ledipasvir and sofosbuvir therapy was administered to 205 patients whose sustained virological responses (SVR) were checked.

Results

Hepatitis C virus was detected in 232 of 258 patients by direct sequencing and in 236 of 258 patients by the PCR‐Invader assay. Forty of 231 cases were defined as Y93 mutation by direct sequencing, and 46 of 236 cases were defined as Y93 mutation by the PCR‐Invader assay. SVR of patients who were Y93H by direct sequencing, Y93H by the PCR‐Invader assay, and Y93H by both methods was 62.5%, 82.4%, and 50%, respectively.

Conclusions

The sensitivity of the PCR‐Invader assay was similar to that of direct sequencing analysis; however, the PCR‐Invader assay had a better ability to detect minor strains. Combination of the two assays would improve prediction of the response to daclatasvir and asunaprevir, but Y93H mutation had little effect on SVR in ledipasvir and sofosbuvir therapy.